Skip to main content
. 2021 Jul 13;2(8):100208. doi: 10.1016/j.jtocrr.2021.100208

Figure 3.

Figure 3

Spider plot of progression-free survival by cycle in arms A and B. In arm A: data unavailable on seven patients owing to death (n = 2), discontinued study therapy owing to adverse event (n = 2), patient noncompliance (n = 1) before first study imaging; imaging not available (n = 1), no measurable disease per response evaluation criteria in solid tumors (n = 1). In arm B: data unavailable on eight patients owing to disease progression (n = 5), discontinued study therapy owing to adverse event (n = 2), or patient death (n = 1) before first study imaging. #, number; CR, complete response; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria for Solid Tumors; SD, stable disease.